Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other ...

Imagine yourself as a passive income investor looking for a medical stock with significant share growth potential. Wall ...

Merck posted strong Q4 earnings, with a 7% revenue increase to $15.62 billion, beating expectations. Growth was driven by ...

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look ...

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...

Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

Sales of new pulmonary arterial hypertension drug, Winrevair, also missed estimates. The decline in Merck’s stock price post-earnings has left investors confused about whether to buy ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.